Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 20/20 | 0.69 |
| ▸ | S1PR3 | Q99500 | 18/20 | 0.60 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.57 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.57 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2008197 | 0.87 | S1PR1 (0.48) | S1PR1S1PR3S1PR4S1PR5 | |
| Hydrochloric Acid SCHEMBL12610226 | 0.85 | S1PR1 (0.47) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL12799739 | 0.84 | S1PR1 (0.70) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL1497854 | 0.84 | S1PR1 (0.81) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL1497928 | 0.84 | S1PR1 (0.81) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL688479 | 0.84 | S1PR1 (0.76) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL4330895 | 0.83 | S1PR1 (0.72) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL12631107 | 0.82 | S1PR1 (0.68) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL12631492 | 0.82 | S1PR1 (0.68) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL13576869 | 0.82 | S1PR1 (0.77) | S1PR1S1PR3S1PR4S1PR5S1PR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509938-A1 | FTY720 HALOGENATED DERIVATIVES | Novartis AG (CH) | 2012-10-17 | — | — | EP | disclosed |
| US-20120244071-A1 | FTY720 HALOGENATED DERIVATIVES | NOVARTIS AG (CH) | 2012-09-27 | — | — | US | disclosed |
| US-20120244071-A1 | FTY720 HALOGENATED DERIVATIVES | NOVARTIS AG (CH) | 2012-09-27 | — | — | US | disclosed |
| WO-2011070066-A1 | FTY720 HALOGENATED DERIVATIVES | NOVARTIS AG (CH) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011070066-A1 | FTY720 HALOGENATED DERIVATIVES | NOVARTIS AG (CH) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120244071-A1 | FTY720 HALOGENATED DERIVATIVES | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR3 2/4885S1PR4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.